The integration of the helical I-125 seed implant with TACE, lenvatinib, and PD-1 inhibitors in the management of HCC concurrent with MPVTT demonstrates a safe and efficacious therapeutic approach. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.